More: CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4...
More: CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4...
Continue reading here: GRI Bio Announces Reverse Stock Split
Visit link: AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines...
View post: Zealand Pharma major shareholder announcement: Van Herk Investments
Visit link: Amphista Therapeutics announces new data demonstrating in vivo efficacy and CNS activity of its mechanistically differentiated targeted protein...
View original post here: SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa
Read the original post: Tilray Brands Completes Acquisition of Truss Beverage Co.
The rest is here: Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
Excerpt from: Renexxion Ireland Ltd. Announces FDA Clearance of Investigational New Drug (IND) Application for Naronapride to Treat PPI-Non-Responsive Symptomatic...
Read the original: Kura Oncology Announces Oversubscribed $150 Million Private Placement
Recent Comments